Ono taps Receptos to identify GCPR-based drug leads
This article was originally published in Scrip
In a deal which might be aimed at building up its existing R&D activities in the oncology field, Ono Pharmaceutical has tied up with Receptos for discovery research into a G-protein-coupled receptor (GPCR) related to a bioactive lipid.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.